financetom
Business
financetom
/
Business
/
Trade Desk tumbles after CEO warns of tariff impact on large brand advertisers
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Trade Desk tumbles after CEO warns of tariff impact on large brand advertisers
Aug 8, 2025 5:07 AM

(Reuters) -Shares of cloud-based ad tech firm Trade Desk fell by a third during premarket trading on Friday, after CEO Jeff Green warned about ongoing tariff uncertainty pressuring some of the world's largest advertisers.

Trade Desk's stock move looked set to wipe out over $12 billion from the company's market valuation, if losses hold.

Changing trade policies have led to concerns about soft ad spending as companies are holding back on launching new campaigns, particularly in sectors directly affected by tariffs.

Trade Desk, which specializes in helping advertisers buy and optimize digital ad campaigns, has concentrated on large global advertisers.

This focus has made the company more vulnerable to wider economic pressures, in contrast to competitors who rely more on small and medium-sized businesses, Green said on Thursday.

"In an unusual development, TTD decelerated and grew slower than Meta's 22%, which marked an acceleration, prompting worries that closed gardens are growing faster than the open Internet," said Rosenblatt Securities analyst Barton Crockett.

"TTD is also meaningfully exposed to large brands, which are facing tariff pressures."

The company expects the current quarter's revenue to be at least $717 million, largely in line with expectations from analysts compiled by LSEG.

At least seven analysts lowered their price targets on the stock following the results, bringing the median target to $84, as per data compiled by LSEG.

Trade Desk on Thursday also named Alex Kayyal as its chief financial officer, effective August 21, succeeding Laura Schenkein.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With Longeveron Stock?
What's Going On With Longeveron Stock?
Apr 15, 2024
Longeveron Inc ( LGVN ). shares are trading higher Monday following insider buys from multiple company executives. Here's a look at what's going on. What To Know: Multiple company executives disclosed large stock purchases after the close on Friday. Joshua Hare, Chief Scientific Officer, purchased 297,872 shares. Rock Soffer, director, purchased 276,596 shares and CEO Mohamed Wa’el Ahmed Hashad purchased...
Tapestry Secures Approvals in EU, Japan for Planned $8.5 Billion Acquisition of Capri Holdings
Tapestry Secures Approvals in EU, Japan for Planned $8.5 Billion Acquisition of Capri Holdings
Apr 15, 2024
11:55 AM EDT, 04/15/2024 (MT Newswires) -- Tapestry (TPR) said in a Monday filing that the European Commission and the Fair Trade Commission of Japan have approved the company's planned $8.5 billion acquisition of Capri Holdings ( CPRI ) . The company said the only pending antitrust regulatory approval for the transaction is in the US but the acquisition's completion...
Rivian Automotive Unusual Options Activity
Rivian Automotive Unusual Options Activity
Apr 15, 2024
Whales with a lot of money to spend have taken a noticeably bearish stance on Rivian Automotive ( RIVN ). Looking at options history for Rivian Automotive ( RIVN ) we detected 21 trades. If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades with bullish expectations and 61% with...
Marinus Pharmaceuticals Shares Fall After Phase 3 Trial Interim Analysis of Ganaxolone
Marinus Pharmaceuticals Shares Fall After Phase 3 Trial Interim Analysis of Ganaxolone
Apr 15, 2024
11:49 AM EDT, 04/15/2024 (MT Newswires) -- Marinus Pharmaceuticals ( MRNS ) shares fell past 79% in recent Monday trading after the company said that a phase 3 trial of ganaxolone did not meet pre-defined stopping criteria at the interim analysis. The study was designed to evaluate intravenous ganaxolone for the treatment of refractory status epilepticus, the company said. An...
Copyright 2023-2026 - www.financetom.com All Rights Reserved